• Molecular NamePerflutren
  • SynonymNA
  • Weight188.017
  • Drugbank_IDDB00556
  • ACS_NO76-19-7, 218599-63-4, 300408-51-9
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)2.99
  • pkaN/A
  • LogD (pH=7, predicted)2.99
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-3.81
  • LogSw (predicted, AB/LogsW2.0)0.04
  • Sw (mg/ml) (predicted, ACD/Labs)0.03
  • No.of HBond Donors0
  • No.of HBond Acceptors0
  • No.of Rotatable Bonds2
  • TPSA0.0
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyThe use of droperidol has been associated with QT interval prolongation, torsade de pointes and other serious arrhythmias, and sudden death. The concurrent administration of perflutren may increase the risk of prolonged QT syndrome. Halofantrine extracellular region
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmN/A
  • Half lifeN/A
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A